CollPlant Biotechnologies (NASDAQ:CLGN) Given “Buy” Rating at D. Boral Capital

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They presently have a $14.00 target price on the stock. D. Boral Capital’s target price suggests a potential upside of 280.43% from the company’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of CollPlant Biotechnologies in a report on Friday, November 29th.

CollPlant Biotechnologies Price Performance

NASDAQ:CLGN traded up $0.02 during midday trading on Wednesday, reaching $3.68. The stock had a trading volume of 13,840 shares, compared to its average volume of 6,623. The stock has a market capitalization of $42.14 million, a P/E ratio of -2.39 and a beta of 0.86. The firm’s fifty day simple moving average is $3.84 and its 200-day simple moving average is $4.29. CollPlant Biotechnologies has a 1-year low of $3.24 and a 1-year high of $6.75.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its earnings results on Wednesday, November 27th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative net margin of 2,680.00% and a negative return on equity of 77.05%. During the same period in the prior year, the company posted ($0.38) EPS. On average, equities research analysts anticipate that CollPlant Biotechnologies will post -1.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CollPlant Biotechnologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AMH Equity Ltd lifted its stake in CollPlant Biotechnologies by 17.4% in the 4th quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after purchasing an additional 17,295 shares during the last quarter. Benjamin Edwards Inc. bought a new stake in CollPlant Biotechnologies in the third quarter valued at approximately $112,000. Finally, Villere ST Denis J & Co. LLC lifted its position in shares of CollPlant Biotechnologies by 24.4% in the third quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock valued at $2,407,000 after buying an additional 95,000 shares during the last quarter. 21.69% of the stock is owned by institutional investors and hedge funds.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.